A Phase 1, Single-center, Randomized, 2-way Crossover, Open Label Study to Evaluate the Effect of Renvela on the Pharmacodynamics of AZD1722 in Healthy Volunteeers

Trial Profile

A Phase 1, Single-center, Randomized, 2-way Crossover, Open Label Study to Evaluate the Effect of Renvela on the Pharmacodynamics of AZD1722 in Healthy Volunteeers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Tenapanor (Primary) ; Sevelamer
  • Indications Hyperphosphataemia; Irritable bowel syndrome; Renal failure
  • Focus Pharmacodynamics
  • Sponsors Ardelyx
  • Most Recent Events

    • 05 Dec 2014 New trial record
    • 23 Oct 2014 Results were presented at the American Society of Nephrology Kidney Week 2014, according to an Ardelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top